Biocept Investor Relations Material
Latest events
Status Update
Biocept
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Biocept Inc
Access all reports
Biocept, Inc., is an early stage molecular oncology diagnostic company developing and commercializing proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Biocept's multi-targeted tests will provide oncologists and their patients with valuable information that may affect the course of treatment decision making in non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), melanoma and other solid tumors. The company's initial efforts are focused on CS-36, a test to detect 31 NSCLC mutations, eight PI3K pathway mutations and an EGFR mutation in circulating tumor cells from patients' blood. Biocept is also pursuing additional indications for use of its CTC assay for detecting malignant circulating tumor cells. The company is based in San Diego, California.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
BIOC
Country
🇺🇸 United States